Artblood is focused on addressing the global shortage of blood supply and the complications associated with blood transfusions through the development of a cell-based in vitro blood production system. The company is also working on a platform for therapeutic red blood cells that can transport and express various treatments and immune stimulants. This innovative approach aims to enhance the safety and availability of blood products, thereby improving patient outcomes in transfusion medicine.

In addition to its blood production initiatives, Artblood is developing a cell line specifically for antibody diagnostic reagents. This cell line is designed to produce red blood cells used in non-specific antibody testing, which is crucial for preventing severe hemolytic transfusion reactions. The company addresses several challenges in the current market, such as reliance on imported reagents and the complexity of interpreting results from mixed blood panels. By ensuring consistent production of customized red blood cells that can detect regionally and ethnically relevant antibodies, Artblood aims to simplify the testing process and expand its offerings both domestically and internationally.

South Korea

Art Blood Co., Ltd. is a company that is building/developing a cell-based in vitro blood production system to solve the problem of blood for transfusion that is in short supply worldwide and has side effects.
In addition, we are developing a platform to provide reagent red blood cells used to detect transfusion-related antibodies and therapeutic red blood cells that transport and express various therapeutic agents and immunostimulants.

Artblood

Company Details